Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference
- 1 January 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 4 (1), 3-11
- https://doi.org/10.1158/2326-6066.cir-15-0279
Abstract
The inaugural International Cancer Immunotherapy Conference, cohosted by the Cancer Research Institute (CRI), the American Association for Cancer Research (AACR), the Association for Cancer Immunotherapy (CIMT), and the European Academy of Tumor Immunology (EATI), was held in New York City on September 16–19, 2015. The conference brought together nearly 1,400 scientists, clinicians, regulators, patient advocates, and other stakeholders to discuss the latest scientific developments in cancer immunology and immunotherapy, as well as the regulatory hurdles facing new drug development. This conference report summarizes the main themes that emerged during the 4-day meeting. Cancer Immunol Res; 4(1); 3–11. ©2016 AACR.Keywords
This publication has 30 references indexed in Scilit:
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptorCancer Gene Therapy, 2015
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensNature, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Adoptive immunotherapy for cancer: harnessing the T cell responseNature Reviews Immunology, 2012
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 2003
- Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanomaProceedings of the National Academy of Sciences, 1998
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proceedings of the National Academy of Sciences, 1993
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991